FDA OKs Marketing of New Test to Help Diagnose Alzheimer Disease - HealthDay News
5/6/2022 12:00:00 AM2 years 11 months ago
by Physician’s Briefing Staff
by Physician’s Briefing Staff
Lumipulse G β-Amyloid Ratio (1-42/1-40) test is first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer disease
FRIDAY, May 6, 2022 (HealthDay News) -- The U.S. Food and Drug Administration granted marketing approval for the Lumipulse G β-Amyloid Ratio (1-42/1-40) test, the first in vitro diagnostic test for … [+2027 chars]
full article...